Research Update

ReNeuron Group plc 06 September 2007 ReNeuron gives AGM update on its ReN001 stem cell therapy for stroke Guildford, UK, 6 September 2007: ReNeuron Group plc (LSE: RENE) today announces an update on progress with its ReN001 stem cell therapy for stroke, ahead of its 2007 Annual General Meeting. In June, the Company stated in its preliminary full year results statement that it was working to conclude a number of pre-clinical studies to provide further data in support of its Interventional New Drug (IND) application to the US Food and Drug Administration (FDA) to commence initial clinical trials with ReN001 in the US. The most important of these is a study examining the long-term safety profile of ReN001 in a specialised pre-clinical model of stroke. This study has now reached its end-point, and, subject to completion of data analysis, no significant or unusual adverse safety effects have been observed in either control or treatment groups. The Company is encouraged by the results both from this study and from the other studies undertaken in support of the IND application. Based on these results, the Company confirms that it remains on track to submit the required IND data package to the FDA in the final quarter of 2007. The AGM will take place today at 10.00am at the offices of Morrison & Foerster MNP, City Point, One Ropemaker Street, London, EC2Y 9AW. Enquiries: ReNeuron Michael Hunt, Chief Executive Officer Tel: +44 (0) 1483 302560 Dr John Sinden, Chief Scientific Officer Europe David Yates Tel: +44 (0) 20 7831 3113 Claire Rowell US Robert Stanislaro Tel : +1 212 850 5657 About ReNeuron ReNeuron is a leading, UK-based stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. The Company operates from laboratories in Surrey, UK and Los Angeles, California, USA. ReNeuron has used its c-mycER technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation. ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. This represents the world's first such filing concerning a neural stem cell treatment for a major neurological disorder. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US. In addition to its stroke programme, ReNeuron is developing stem cell therapies for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of the retina. The Company recently announced the acquisition of the business assets of AmCyte Inc. in the US, bringing clinically-tested cell encapsulation technology to ReNeuron's ReN002 diabetes programme. ReNeuron has leveraged its stem cell technologies into non-therapeutic areas - its ReNcell(R) range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron's ReNcell(R)CX and ReNcell(R)VM neural cell lines are marketed worldwide under license by Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. Data sources: UK Stroke Association; American Stroke Association. This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as 'should', 'expects', 'estimates', 'believes' or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings